Q32 Bio (QTTB) Projected to Announce Earnings on Thursday

Key Points

• Q32 Bio is expected to report Q3 2026 earnings before the market opens Thursday, November 12, with analysts forecasting a loss of $0.36 per share.
• In its reported quarter, the company lost $0.26 per share, beating the $0.33-per-share loss analysts expected; revenue was $0.17 million, in line with estimates.
• Analysts’ consensus rating is “Moderate Buy”, with an average price target of $32.17. Recent targets include $36 from HC Wainwright and $40 from Leerink Partners.

Q32 Bio (NASDAQ:QTTB - Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.36) per share for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 7:00 AM ET.

Q32 Bio (NASDAQ:QTTB - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.07. The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.17 million. On average, analysts expect Q32 Bio to post ($1.54) EPS for the current fiscal year and ($1.85) EPS for the next fiscal year.

Q32 Bio Stock Performance

Q32 Bio stock opened at $8.97 on Thursday. The business's 50-day simple moving average is $10.00 and its 200-day simple moving average is $9.30. The firm has a market capitalization of $267.04 million, a PE ratio of 4.23 and a beta of 0.45. Q32 Bio has a 52 week low of $1.90 and a 52 week high of $23.57.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Weiss Ratings upgraded Q32 Bio from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, August 21st. HC Wainwright lifted their price target on Q32 Bio from $13.00 to $36.00 and gave the stock a "buy" rating in a research report on Tuesday, July 28th. Mizuho raised Q32 Bio to a "strong-buy" rating in a research report on Monday, September 7th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Q32 Bio in a report on Wednesday, September 16th. Finally, Leerink Partners started coverage on Q32 Bio in a research report on Monday, October 12th. They issued an "outperform" rating and a $40.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $32.17.

Insider Buying and Selling

In related news, CFO Lee Kalowski sold 3,972 shares of the business's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total transaction of $65,776.32. Following the transaction, the chief financial officer directly owned 138,471 shares in the company, valued at $2,293,079.76. The trade was a 2.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jodie Morrison sold 3,221 shares of the company's stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $8.32, for a total value of $26,798.72. Following the completion of the transaction, the chief executive officer directly owned 340,038 shares of the company's stock, valued at approximately $2,829,116.16. This trade represents a 0.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 22,054 shares of company stock valued at $320,397 over the last three months. 34.46% of the stock is owned by corporate insiders.

About Q32 Bio

Q32 Bio Inc NASDAQ: QTTB is a clinical-stage biotechnology company focused on developing biologic therapies for diseases associated with immune-system dysfunction. The company's research programs are designed to restore immune balance rather than broadly suppress immune activity.

Q32 Bio's lead product candidate is bempikibart, formerly known as ADX-914, a fully human monoclonal antibody that targets activin receptor type IIA (ActRIIA). The company has evaluated bempikibart in inflammatory and autoimmune conditions, including atopic dermatitis and alopecia areata.

The company also has pursued additional immunology programs, including therapies intended to address complement-mediated disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.